Breakthrough Genomics

2 Hughes, Suite 100 Irvine, CA 92618 Phone: (949) 381-3794 info@btgenomics.com www.btgenomics.com

CAMBIOLOGI GENETI	C TEST REQUISITION TOR	1 7 1	
	PATIENT IN	FORMATION	
Patient Last Name:	Patient First N	lame:	MI
Date of Birth (MM/DD/YY):	Sex 🗆 Male 🗆	Female	Ethnic Background (check all that apply)
Address:			☐ African American ☐ Asian/Pacific Islander
City:	State:Zip):	☐ Caucasian ☐ Hispanic ☐ Mediterranean
	E-mail:		
		CIAN INFORMATION	Tradive American
Name (Last First ML):			Institution Name:
			State:Zip:
	cipient:		Location ID:
SAMPLE INFO	☐ Website Portal ☐ Fax ☐ Mail ☐		LINICAL INFORMATION
Date Collected:		Clinical indications: _	
·	(Lab Use Only)		
Collected By:	Volume:	ICD-10 codes:	-
	urple-top tube) 🗆 Saliva 🗆 DNA		
Please check all of the following s			transfusion within the past 30 days
☐ Patient has had bone marr	·	☐ Patient or imme	ediate family member is pregnant
	Institution Name and Contact:		
☐ MEDICARE/MEDICAID N	Medicare/Medicaid No		State:
\square INSURANCE BILLING Please include a copy of insurance card(s) both front and back for billing purposes			
Policyholder Name	DOB (MM/I	DD/YY)	Phone No
Insurance Co	Member ID		Group No
☐ SELF PAYMENT (Invoice for	r payment will be issued upon receipt of	sample. Please complet	ely fill out patient's address to avoid delay of
	Patient /Guardian Acknowled	_	
directly to Breakthrough Genom financially responsible for any ar	ics and authorize them to release medio mounts not covered by my insurer for the s any money received from my health in	cal information concern nis test order. I also fully	by authorize my insurance benefits to be paid ing my testing to my insurer. I understand that I am understand that I am legally responsible for ne performance of this genetic test. Failing to do so
Patient/Guardian's Name:	Patient/Guardiar	n's Signature:	Date:

Breakthrough Genomics

2 Hughes, Suite 100 Irvine, CA 92618 Phone: (949) 381-3794 info@btgenomics.com

www.btgenomics.com

CANDIOLOGI GENETIC TEST NEQOISTITION FORM		
	STATEMENT OF MEDICAL NECESS	SITY
Inf	ormed Consent and Statement of Medi	cal Necessity
be performed. I further confirm that this test is	medically necessary for the diagnosis ced in the medical management and tre	patient/guardian has given consent for genetic testing to or detection of a disease, illness, impairment, symptom, eatment decisions for the patient. I confirm that the est(s) requested herein.
Physician's Name:	Physician's Signature:	Date:

Breakthrough Genomics

2 Hughes, Suite 100 Irvine, CA 92618 Phone: (949) 381-3794 info@btgenomics.com

www.btgenomics.com

DGUE CONTRACTOR OF THE PROPERTY OF THE PROPERT
☐ Heterotaxy and Situs Inversus Panel
☐ Hyperlipidemia Core Panel
☐ Hyperlipidemia Panel
☐ Hypertrophic Cardiomyopathy (HCM) Panel
\Box Left Ventricular Non-Compaction Cardiomyopathy (LVNC) Panel
☐ Liddle Syndrome Panel
☐ Long QT Syndrome (LQTS) Panel
☐ Marfan Syndrome Panel
☐ Noonan Syndrome Panel
\square Pulmonary Artery Hypertension (PAH) Panel
☐ Short QT Syndrome (SQTS) Panel
. 18
ical Note Must Be Attached)
y age of diagnosis after each diagnosis)

Breakthrough Genomics

2 Hughes, Suite 100 Irvine, CA 92618 Phone: (949) 381-3794 info@btgenomics.com

www.btgenomics.com

CARDIOLOGY GENETIC TEST REQUISITION FORM

INFORMED CONSENT FOR GENETIC TESTING

First Name:	Last Name:
DOB (MM/DD/YYYY): I understand that my health care provider has ordered the f	following genetic testing for {me/my child}:
This is a voluntary test to identify gene mutation associated prior to signing this form. Read this form carefully before m	with hereditary disease and health risks and you may wish to seek genetic counseling baking your decision about testing.

PURPOSE

I am interested in obtaining a genetic test by submitting a biological sample of my own (blood, saliva, or other tissue). The purpose of this molecular genetic test is to ascertain if I am or my child is carrying mutation(s) predisposing to or causing disease or elevated health risks. The biological sample submitted is required for isolation and purification of DNA and molecular genetic testing by next generation sequence analysis of genes associated with hereditary health risks.

THE FOLLOWING POINTS WERE EXPLAINED AND I UNDERSTAND THAT:

- 1. Due to the complexity of DNA based testing and the implications of the results, these results will be reported only through my designated physician(s) or genetic counselor (where allowed) and that I must contact my provider to obtain the results of the test. The test results, in addition, could be released to all who, by law, may have access to such data.
- 2. DNA-based studies performed are specific to the condition indicated above. The results should be evaluated in the context of personal and family health history, the results of physical examination, laboratory and hospital test, and clinical impression of my healthcare provider. I understand that possible result outcomes include positive, negative, and uncertain.
- 3. If results of the tests are uncertain (in the case of variants of unknown clinical significance), meaning that there is not enough information to determine whether this change is associated with an increased risk after thorough search of current literature and databases.
- 4. Unexpected results may be revealed from this test in rare instances. This test is designed to detect changes in genes that predispose a person to a certain health condition; however, it can sometimes uncover genetic conditions in a family unrelated to the targeted disease risks. Results also have the potential to reveal unexpected biological relationships, such as a different biological parent.
- 5. It is the responsibility of the referring physician or health care provider to understand the specific utility and limitations of the testing ordered, and to educate the patient regarding these limitations. While this test is designed to identify most detectable mutations in the genes analyzed, it is still possible there are mutations that this testing technology is unable to detect. In addition, there may be other genes associated with disease susceptibility that are not included on this panel or that are not known at this time.
- 6. The molecular genetic test occasionally may not generate results and that an additional blood, saliva, or tissue sample may be needed to obtain interpretable results.
- 7. Inaccurate results, though rare, may occur for the following reasons: sample mix-up, samples unavailable from critical family members, maternal contamination of prenatal samples, inaccurate reporting of family relationships, or technical problems, but not limited to these.
- 8. The genetic tests results have implications for blood relatives. In consultation with an appropriate healthcare provider, I may wish to discuss sharing the test results with certain blood relatives who may be at risk.

Breakthrough Genomics

2 Hughes, Suite 100 Irvine, CA 92618 Phone: (949) 381-3794 info@btgenomics.com www.btgenomics.com

CARDIOLOGY GENETIC TEST REQUISITION FORM

LISE OF SPECIMENS FOR RESEARCH

Guardian Signature: _____

After testing is completed, I understand that leftover blood, saliva, or tiss identified research, test validation, and/or education as long as my privace the specimens submitted. I understand that I may refuse to submit my specontacting the laboratory. I understand that my refusal to consent to meet If neither box is marked, consent is implied. Consent to the use of my sample for anonymous research: Yes No	y is maintained. I understand that no compensationwill be given for using ecimen for use in this way and may withdraw my consent at any time by
OPT OUT REQUEST I choose to opt out of receiving test results in the following disease categ Adult onset cancer Carrier screening Adult onset neurological diseases	ories:
Other	
· · · · · · · · · · · · · · · · · · ·	ntinues to be new information and data. It is recommended that I keep in opments in medical genetics and to provide any updates to my personal or
PATIENT/GUARDIAN CONSENT STATEMENT	
By signing below, I, the patient or Guardian having the test performed, ac I have read or have had read to me all of the above statements and under questions. I understand the procedure, the risks, benefits, limitations and consent form.	rstand the information above and have had the opportunityto ask
Patient Name:	Date:
Patient Signature:	
Guardian Name:	Date:

Breakthrough Genomics

2 Hughes, Suite 100 Irvine, CA 92618 Phone: (949) 381-3794 info@btgenomics.com www.btgenomics.com

Cardio Related Panels with Payable ICDs		
Cardio Related Panels With Payable ICDs Panel Name ICDs		
i and Name	I35.0 - Nonrheumatic aortic (valve) stenosis	
	I35.1 - Nonrheumatic aortic (valve) insufficiency	
Aorta Panel	I35.2 - Nonrheumatic aortic (valve) stenosis with insufficiency	
	I35.8 - Other nonrheumatic aortic valve disorders	
	I35.9 - Nonrheumatic aortic valve disorder, unspecified	
	155.5 Nonneamatic dorte valve disorder, dispectified	
	I49.01 - Ventricular fibrillation	
	149.02 - Ventricular flutter	
	I49.1 - Atrial premature depolarization	
	I49.2 - Junctional premature depolarization	
	I49.3 - Ventricular premature depolarization	
	I49.40 - Unspecified premature depolarization	
	149.49 - Other premature depolarization	
Arrhythmia Panel	149.5 - Sick sinus syndrome	
	I49.8 - Other specified cardiac arrhythmias	
	I49.9 - Cardiac arrhythmia, unspecified	
	R00.0 - Tachycardia, unspecified	
	R00.1 - Bradycardia, unspecified	
	R00.2 - Palpitations	
	R00.8 - Other abnormalities of heart beat	
	R00.9 - Unspecified abnormalities of heart beat	
	I42.0 - Dilated cardiomyopathy	
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)	I42.1 - Obstructive hypertrophic cardiomyopathy	
Panel	I42.3 - Endomyocardial (eosinophilic) disease	
	I42.8 - Other cardiomyopathies	
	T	
	I48.0 - Paroxysmal atrial fibrillation	
	I48.1 - Persistent atrial fibrillation	
	148.2 - Chronic atrial fibrillation	
Atrial Fibrillation Panel	I48.3 - Typical atrial flutter	
	I48.4 - Atypical atrial flutter	
	I48.91 - Unspecified atrial fibrillation	
	I48.92 - Unspecified atrial flutter	
	I49.01 - Ventricular fibrillation	
	I49.02 - Ventricular flutter	
	I49.1 - Atrial premature depolarization	
	I49.2 - Junctional premature depolarization	
	I49.3 - Ventricular premature depolarization	
Brugada Syndrome Panel	I49.40 - Unspecified premature depolarization	
Diagada Syriai Offic Fafici	I49.49 - Other premature depolarization	
	I49.5 - Sick sinus syndrome	
	I49.8 - Other specified cardiac arrhythmias	
	149.9 - Cardiac arrhythmia, unspecified	
	R00.0 - Tachycardia, unspecified	
	R00.1 - Bradycardia, unspecified	

Breakthrough Genomics

2 Hughes, Suite 100 Irvine, CA 92618 Phone: (949) 381-3794 info@btgenomics.com www.btgenomics.com

CARDIOLOGY GENETIC TEST REQUISITION FORM

CARDIOLOGY GENETIC TEST REQUIS	ITION FORM
	R00.2 - Palpitations
	R00.8 - Other abnormalities of heart beat
	R00.9 - Unspecified abnormalities of heart beat
	_
	I42.0 - Dilated cardiomyopathy
	I42.1 - Obstructive hypertrophic cardiomyopathy
	I42.3 - Endomyocardial (eosinophilic) disease
Cardiomyopathy Panel	I42.4 - Endocardial fibroelastosis
 	I42.5 - Other restrictive cardiomyopathy
	I42.6 - Alcoholic cardiomyopathy
	I42.7 - Cardiomyopathy due to drug and external agent
L	I42.8 - Other cardiomyopathies
Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Panel	l47.2 - Ventricular tachycardia
(Crv1) railei	147.2 - Ventriculai tacifycarula
	I25.10 - Atherosclerotic heart disease of native coronary artery without angina
	pectoris
	I48.91 - Atrial Fibrillation
	I50.9 - Congestive Heart Failure
	163.9 - CVA
	163.9 - Stroke
	I65.23 - Carotid Artery Occlusion, Bilateral
	165.23 - Carotid Artery Stenosis, Bilateral
	165.29 - Carotid Artery Occlusion
	165.29 - Carotid Artery Stenosis
	167.2 - Cerebral Atherosclerosis
Comprehensive Cardiology Panel	167.9 - Ischaemic Cerebrovascular Disease
	173.9 - Peripheral Vascular Disease
	I20.9 - Angina Pectoris, NOS
	I21.09 - Myocardial Infarction,Acute,Anterior
	I21.3 - Myocardial infarction, acute unspecified
	I25.10 - ASHD Coronary Artery
	I25.2 - Old Myocardial Infarction
	125.84 - Coronary Atherosclerosis due to calcified Coronary Lesion
	I25.9 - Chronic Ischaemic Heart Disease
	I11.0 - Malignant Hypertension Heart Disease with Heart Failure
	I11.9 - Benign Hypertension Heart Disease without Heart Failure
	Q24.0 - Dextrocardia
	Q24.1 - Levocardia
	Q24.2 - Cor triatriatum
	Q24.3 - Pulmonary infundibular stenosis
Congenital Structural Heart Disease Panel	Q24.4 - Congenital subaortic stenosis
componition of detailed Florence Lanci	Q24.5 - Malformation of coronary vessels
	Q24.6 - Congenital heart block
	Q24.7 - Other specified congenital malformations of heart

Q24.8 - Other specified congenital malformations of heart Q24.9 - Congenital malformation of heart, unspecified

Breakthrough Genomics

2 Hughes, Suite 100 Irvine, CA 92618 Phone: (949) 381-3794 info@btgenomics.com www.btgenomics.com

Dilated Cardiomyopathy (DCM) Panel	I42.0 - Dilated cardiomyopathy
Ehlers-Danlos Syndrome Panel	Q79.60 - Ehlers-Danlos syndrome, unspecified
and syndrome runer	27.5.00 Emers bullios syndrome, unspecifica
Hereditary Hemorrhagic Telangiectasia (HHT) Panel	I78. 0 - Hereditary hemorrhagic telangiectasia
	•
Heterotaxy and Situs Inversus Panel	Q89.3 - Situs inversus
reterotaxy and situs inversus Faner	Q24.8 - Other specified congenital malformations of heart
	E78.0 - Pure hypercholesterolemia
	E78.00 - Pure hypercholesterolemia, unspecified
	E78.01 - Familial hypercholesterolemia
	E78.1 - Pure hyperglyceridemia
	E78.2 - Mixed hyperlipidemia
	E78.3 - Hyperchylomicronemia
	E78.4 - Other hyperlipidemia
	E78.41 - Elevated Lipoprotein(a)
	E78.49 - Other hyperlipidemia
Hyperlipidemia Core Panel	E78.5 - Hyperlipidemia, unspecified
	E78.6 - Lipoprotein deficiency
	E78.70 - Disorder of bile acid and cholesterol metabolism
	E78.71 - Barth syndrome
	E78.72 - Smith-Lemli-Opitz syndrome
	E78.79 - Other disorders of bile acid and cholesterol
	E78.81 - Lipoid dermatoarthritis
	E78.89 - Other lipoprotein metabolism disorders
	E78.9 - Disorder of lipoprotein metabolism , unspecified
	E78.0 - Pure hypercholesterolemia
	E78.00 - Pure hypercholesterolemia, unspecified
	E78.01 - Familial hypercholesterolemia
	E78.1 - Pure hyperglyceridemia
	E78.2 - Mixed hyperlipidemia
	E78.3 - Hyperchylomicronemia
	E78.4 - Other hyperlipidemia
	E78.41 - Elevated Lipoprotein(a)
	E78.49 - Other hyperlipidemia
Hyperlipidemia Panel	E78.5 - Hyperlipidemia, unspecified
	E78.6 - Lipoprotein deficiency
	E78.70 - Disorder of bile acid and cholesterol metabolism
	E78.71 - Barth syndrome
	E78.72 - Smith-Lemli-Opitz syndrome
	E78.79 - Other disorders of bile acid and cholesterol
	E78.81 - Lipoid dermatoarthritis
	E78.89 - Other lipoprotein metabolism disorders
	E78.9 - Disorder of lipoprotein metabolism , unspecified
Hypertrophic Cardiomyopathy (HCM) Panel	I42.1 - Obstructive hypertrophic cardiomyopathy
	I42.2 - Other hypertrophic cardiomyopathy

Breakthrough Genomics

2 Hughes, Suite 100 Irvine, CA 92618 Phone: (949) 381-3794 info@btgenomics.com

www.btgenomics.com

Left Ventricular Non-Compaction Cardiomyopathy (LVNC)	
Panel	142.8 - Other cardiomyopathies
Liddle Syndrome Panel	I15.1 - Hypertension secondary to other renal disorders
Long QT Syndrome (LQTS) Panel	I45.81 - Long QT syndrome
Long Q1 Syndrome (LQ1S) Panel	145.01 - Long Q1 Syndrome
Marfan Syndrome Panel	Q87.40 - Marfan's syndrome, unspecified
Noonan Syndrome Panel	Q87.19 - Other congenital malformation syndromes predominantly associated with short stature
Pulmonary Artery Hypertension (PAH) Panel	I27.21 - Secondary pulmonary arterial hypertension
Short QT Syndrome (SQTS) Panel	I45.81 - Long QT syndrome